[go: up one dir, main page]

MX2022008164A - Método para obtener una línea celular de mamífero que expresa una gonadotropina coriónica equina recombinante (recg), las líneas celulares recombinantes que producen recg, método de producción de recg a gran escala, recg, formulaciones que contienen recg, ácidos nucleicos que codifican recg y usos. - Google Patents

Método para obtener una línea celular de mamífero que expresa una gonadotropina coriónica equina recombinante (recg), las líneas celulares recombinantes que producen recg, método de producción de recg a gran escala, recg, formulaciones que contienen recg, ácidos nucleicos que codifican recg y usos.

Info

Publication number
MX2022008164A
MX2022008164A MX2022008164A MX2022008164A MX2022008164A MX 2022008164 A MX2022008164 A MX 2022008164A MX 2022008164 A MX2022008164 A MX 2022008164A MX 2022008164 A MX2022008164 A MX 2022008164A MX 2022008164 A MX2022008164 A MX 2022008164A
Authority
MX
Mexico
Prior art keywords
recg
cell line
pmsg
expresses
hormone
Prior art date
Application number
MX2022008164A
Other languages
English (en)
Inventor
Natalia Ceaglio
Claudio Prieto
Diego Fontana
Celeste Rodriguez
Belén Tardivo
Sebastián Antuña
Original Assignee
Univ Nacional Del Litoral
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nacional Del Litoral filed Critical Univ Nacional Del Litoral
Publication of MX2022008164A publication Critical patent/MX2022008164A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención describe un método para obtener una línea celular de mamífero que expresa una hormona gonadotropina coriónica equina recombinante (reCG). También se describen una línea celular que expresa reCG, un método a gran escala para producir reCG, una reCG con una actividad biológica mayor con respecto a PMSG, formulaciones que contienen reCG, ácidos nucleicos que codifican reCG y usos.
MX2022008164A 2019-12-30 2020-12-23 Método para obtener una línea celular de mamífero que expresa una gonadotropina coriónica equina recombinante (recg), las líneas celulares recombinantes que producen recg, método de producción de recg a gran escala, recg, formulaciones que contienen recg, ácidos nucleicos que codifican recg y usos. MX2022008164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP190103911A AR117743A1 (es) 2019-12-30 2019-12-30 MÉTODO DE OBTENCIÓN DE UNA LÍNEA CELULAR DE MAMÍFERO QUE EXPRESA UNA HORMONA GONADOTROFINA CORIÓNICA EQUINA RECOMBINANTE (reCG), LÍNEA CELULAR QUE EXPRESA reCG, MÉTODO DE PRODUCCIÓN A ESCALA DE reCG, reCG, FORMULACIONES QUE LA CONTIENEN, ÁCIDOS NUCLEICOS QUE CODIFICAN PARA reCG Y USOS
PCT/EP2020/087779 WO2021136736A1 (en) 2019-12-30 2020-12-23 Method for obtaining a mammalian cell line that expresses a recombinant equine chorionic gonadotropin (recg), the recombinant cell lines producing recg, large-scale recg production method, recg, formulations containing recg, nucleic acids encoding for recg and uses

Publications (1)

Publication Number Publication Date
MX2022008164A true MX2022008164A (es) 2022-10-18

Family

ID=74194697

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008164A MX2022008164A (es) 2019-12-30 2020-12-23 Método para obtener una línea celular de mamífero que expresa una gonadotropina coriónica equina recombinante (recg), las líneas celulares recombinantes que producen recg, método de producción de recg a gran escala, recg, formulaciones que contienen recg, ácidos nucleicos que codifican recg y usos.

Country Status (11)

Country Link
US (1) US20230242608A1 (es)
EP (1) EP4085071A1 (es)
JP (1) JP2023510521A (es)
CN (1) CN115244072B (es)
AR (1) AR117743A1 (es)
AU (1) AU2020418449A1 (es)
BR (1) BR112022013072A2 (es)
CO (1) CO2022010567A2 (es)
MX (1) MX2022008164A (es)
WO (1) WO2021136736A1 (es)
ZA (1) ZA202207247B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024262053A1 (ja) * 2023-06-20 2024-12-26 株式会社バイオ未来工房 幹細胞培養用培地、細胞産生タンパク質組成物、および骨芽前駆細胞または骨芽細胞への分化誘導方法
CN121241128A (zh) * 2023-06-20 2025-12-30 生物未来工房株式会社 干细胞培养用培养基、细胞产生蛋白质组合物和诱导分化为成骨前体细胞或成骨细胞的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1036398A (ja) * 1996-07-25 1998-02-10 Denki Kagaku Kogyo Kk 性腺刺激ホルモンの製造法
ES2414705T3 (es) * 2003-06-20 2013-07-22 Ares Trading S.A. Formulaciones liofilizadas de FSH/LH
US8604175B2 (en) * 2005-12-09 2013-12-10 Ares Trading S.A. Method for purifying FSH or a FSH mutant
BR112015028737B1 (pt) * 2013-05-16 2022-05-10 Universidade De São Paulo - Usp Métodos para a produção e/ou purificação de hormônios
CN107979973A (zh) * 2015-05-04 2018-05-01 法国化学与生物科技实验室 Fc融合蛋白质的转基因生产
WO2016178087A1 (en) * 2015-05-04 2016-11-10 Biosourcing Sa Transgenic production of chorionic gonadotropin
BR102015032660B1 (pt) 2015-12-28 2019-05-28 Ouro Fino Saúde Animal Participações S.A. PROCESSO DE PRODUÇÃO DE UMA GONADOTROFINA CORIÔNICA EQUINA RECOMBINANTE (reCG): COMPOSIÇÃO VETERINÁRIA E USO
EP3398609A4 (en) * 2015-12-28 2019-05-08 Ouro Fino Saúde Animal Participações S.A. METHOD FOR PRODUCING A RECOMBINANT HORSE-CHORIONGONADOTROPIN, VETERINARY COMPOSITION AND ITS USE
BR102016006222A2 (pt) * 2016-03-22 2017-09-26 Universidade De São Paulo - Usp Process of production and purification of recombinant hydrogen hydrogen hybrid or non-hybrid, recombinant hydrogen hydrogen hybrids or non-hybrid, vectors of expression, and uses of recombinant glicoprotetic hormones
CN109336981A (zh) * 2018-09-19 2019-02-15 北京伟杰信生物科技有限公司 一种重组马绒毛膜促性腺激素融合蛋白及其制备方法和其应用

Also Published As

Publication number Publication date
EP4085071A1 (en) 2022-11-09
CN115244072B (zh) 2025-11-25
AR117743A1 (es) 2021-08-25
CO2022010567A2 (es) 2023-02-16
JP2023510521A (ja) 2023-03-14
WO2021136736A1 (en) 2021-07-08
ZA202207247B (en) 2023-03-29
BR112022013072A2 (pt) 2022-12-13
CN115244072A (zh) 2022-10-25
AU2020418449A1 (en) 2022-07-21
US20230242608A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
Dilworth et al. Microbial expression systems for membrane proteins
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
CL2024000835A1 (es) Sistemas de represores de casx diseñados por ingeniería genética
CO2017006870A2 (es) Métodos de producción de polipéptidos de hormona de crecimiento modificada por ctp
NZ756132A (en) Method for producing multispecific antibodies
MX2021014712A (es) Polipeptidos de transposasa y sus usos.
MX2019004499A (es) Sistemas de replicón de virus recombinante y usos de estos.
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
MX2021000934A (es) Linfocitos t que contienen nef y métodos para producirlos.
MX2022008164A (es) Método para obtener una línea celular de mamífero que expresa una gonadotropina coriónica equina recombinante (recg), las líneas celulares recombinantes que producen recg, método de producción de recg a gran escala, recg, formulaciones que contienen recg, ácidos nucleicos que codifican recg y usos.
MX2010004397A (es) Celula para uso en la produccion de proteina exogena y proceso de produccion que utiliza la celula.
PH12022551580A1 (en) Anti-ctla-4 antibody and use thereof
WO2014097113A3 (en) Production of therapeutic proteins in genetically modified mammalian cells
WO2019121961A3 (en) Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin
WO2012168788A3 (en) Baculoviral dna elements for the expression of recombinant proteins in a host cell
AR115417A1 (es) Método para clasificar material vegetal
WO2021133959A3 (en) Compositions and methods for gamma delta tcr reprogramming using fusion proteins
BR112022012915A2 (pt) Polipeptídeo que tem atividade de d-xilulose 4-epimerase, método para produzi-lo, uso deste, polinucleotídeo isolado, construto de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para converter d-xilulose em l-ribulose, método e uso de um polipeptídeo para preparar l-pentose
EP4219763A3 (en) Method for quantifying gene fusion dna
WO2018224035A8 (en) Polypeptide, use and method for hydrolysing protein
JP2017524366A5 (es)
CO2018006654A2 (es) Proceso de producción de una gonadotrofina coriónica equina recombinante (recg), composición veterinaria y uso
HK1254383A1 (zh) 增强木糖的微藻代谢
MX2024004692A (es) Celulas de mamifero que comprenden genes cas9 integrados para producir sitios de integracion estables, y celulas de mamifero que comprenden sitios de integracion estables y otros sitios.
Miyashita et al. Corrigendum: Long-term channelrhodopsin-2 (ChR2) expression can induce abnormal axonal morphology and targeting in cerebral cortex